Results 181 to 190 of about 2,201,777 (199)

Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC

Advanced Healthcare Materials
AbstractAcquired resistance to osimertinib (Osi) remains a major obstacle in the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). AXL elevation is a known key mechanism of Osi‐resistance, and therapeutic strategies remain scarce.
Yuanyao Dou, Yihui Liu, Rui Han, Jie Zheng, Liping Wang, Chen Hu, Daijuan Huang, Chao He, Yimin Zhang, Caiyu Lin, Conghua Lu, Di Wu, Huan Tang, Tingting He, Liling Tang, Yong He   +15 more
openaire   +2 more sources

Resistance beyond osimertinib

Lung Cancer, 2019
R. Powell, R. Kussaibati, S. Baijal
openaire   +1 more source

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

International Journal of Molecular Sciences, 2022
Brigida Stanzione, Alessandra Bearz, Alessandro Del Conte   +2 more
exaly  

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Journal of Thoracic Oncology, 2023
Noura Choudhury
exaly  

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge

Cancers, 2022
Edurne Arriola
exaly  

Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy

Clinical Lung Cancer, 2019
Michael J, Jelinek, Samantha A, Armstrong, Jyoti D, Patel, Deepa S, Subramaniam   +3 more
openaire   +2 more sources

Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling

Toxicology and Applied Pharmacology, 2021
Lai Jianjun, Zhibing Wu
exaly  

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer

European Journal of Cancer, 2021
Shinkyo Yoon, Deokhoon Kim, Kyoungmin Lee   +2 more
exaly  

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Lung Cancer, 2016
Siraj M Ali, Sai-Hong Ou
exaly  

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer

Clinical Oncology, 2021
exaly